The Lancet Regional Health - Europe, Journal Year: 2023, Volume and Issue: 35, P. 100790 - 100790
Published: Nov. 17, 2023
Language: Английский
Vaccine, Journal Year: 2024, Volume and Issue: 42(15), P. 3389 - 3396
Published: April 22, 2024
Language: Английский
Citations
9
Eurosurveillance, Journal Year: 2024, Volume and Issue: 29(3)
Published: Jan. 18, 2024
We conducted a multicentre hospital-based test-negative case–control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during Omicron XBB lineage-predominant period in patients aged ≥ 60 years with severe acute respiratory from five countries Europe. Bivalent provided short-term additional protection compared those vaccinated > 6 months before campaign: 80% (95% CI: 50 94) for 14–89 days post-vaccination, 15% −12 35) at 90–179 days, and lower no effect thereafter.
Language: Английский
Citations
8
Eurosurveillance, Journal Year: 2024, Volume and Issue: 29(37)
Published: Sept. 12, 2024
BackgroundLong-term effectiveness data on bivalent COVID-19 boosters are limited.AimWe evaluated the long-term protection of against severe among ≥ 65-year-olds in Finland.MethodsIn this register-based cohort analysis, we compared risk three outcomes who received a booster (Original/Omicron BA.1 or Original/BA.4-5; exposed group) between 1/9/2022 and 31/8/2023 to those did not (unexposed). We included individuals vaccinated with at least two monovalent vaccine doses before 3 months ago. The analysis was divided into periods: 1/9/2022-28/2/2023 (BA.5 BQ.1.X predominating) 1/3/2023-31/8/2023 (XBB predominating). hazards for unexposed were Cox regression.ResultsWe 1,191,871 individuals. From 28/2/2023, associated reduced hospitalisation due (hazard ratio (HR): 0.45; 95% confidence interval (CI): 0.37-0.55), death (HR: 0.49; CI: 0.38-0.62), which contributing factor 0.40; 0.31-0.51) during 14-60 days since vaccination. 1/3/2023 31/8/2023, lower risks all 61-120 (e.g. HR: 0.53; 0.39-0.71 COVID-19); thereafter no notable reduction observed. No difference found Original/Omicron Original/BA.4-5 boosters.ConclusionBivalent initially by ca 50% 65-year-olds, but waned over time. These findings help guide development vaccination programmes.
Language: Английский
Citations
7
EClinicalMedicine, Journal Year: 2024, Volume and Issue: 71, P. 102587 - 102587
Published: April 10, 2024
The Sanofi/GSK AS03-adjuvanted (VidPrevtyn Beta) vaccine and the Pfizer-BioNTech mRNA (Comirnaty Original/Omicron BA.4-5) bivalent were offered to adults aged 75 years over in England from 3rd April 2023. This is first time an adjuvanted COVID-19 has been administered as part of a UK vaccination programme. In clinical trials, antibody levels generated comparable with vaccines but there are no real-world data on effectiveness or duration protection.
Language: Английский
Citations
6
Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15
Published: May 2, 2024
Background The assessment of long-term humoral and cellular immunity post-vaccination is crucial for establishing an optimal vaccination strategy. Methods This prospective cohort study evaluated adults (≥18 years) who received a BA.4/5 bivalent vaccine. We measured the anti-receptor binding domain immunoglobulin G antibody neutralizing antibodies (NAb) against wild-type Omicron subvariants (BA.5, BQ.1.1, BN.1, XBB.1 EG.5) up to 9 months post-vaccination. T-cell immune responses were before 4 weeks after vaccination. Results A total 108 (28 SARS-CoV-2-naïve 80 previously infected) participants enrolled. Anti-receptor (U/mL) levels higher at than baseline in SAR-CoV-2-naïve individuals (8,339 vs. 1,834, p<0.001). NAb titers significantly both groups, whereas EG.5 was negligible all time points. response (median spot forming unit/10 6 cells) highly cross-reactive (wild-type/BA.5/XBB.1.5, 38.3/52.5/45.0 individuals; 51.6/54.9/54.9 SARS-CoV-2-infected individuals) post-vaccination, with insignificant boosting Conclusion Remarkable neutralization observed vaccination, but not EG.5. cross-reactive.
Language: Английский
Citations
4
Vaccine, Journal Year: 2025, Volume and Issue: 53, P. 126948 - 126948
Published: March 1, 2025
In England, and many other countries, immunity to SARS-CoV-2 infection COVID-19 disease is highly heterogeneous. Immunity has been acquired through natural infection, primary booster vaccination, while protection lost waning viral mutation. During the height of pandemic in main aim was rapidly protect population large supplies vaccine were pre-purchased, eliminating need for cost-effective calculations. As we move an era where majority infections cause relatively mild disease, stocks be re-purchased, it important consider cost-effectiveness economic value vaccination programmes. Here using data from 2023 2024 England on hospital admissions, ICU admissions deaths, coupled with bespoke health costs, willingness pay threshold vaccines different age risk groups. Willingness thresholds vary less than £1 younger age-groups without any factors, over £100 older comorbidities that place them at risk. This extreme non-linear dependence age, means despite method estimating effectiveness, there considerable qualitative agreement threshold, therefore which ages vaccinate. The historic offer those 65 autumn programme 75 spring programme, aligns our cost- effective pre-purchased when only cost administration. However, future programmes, costs are included, age-thresholds slowly increase thereby demonstrating continued importance protecting eldest most vulnerable population.
Language: Английский
Citations
0
Vaccine, Journal Year: 2025, Volume and Issue: 53, P. 126955 - 126955
Published: March 10, 2025
Language: Английский
Citations
0
Vaccines, Journal Year: 2024, Volume and Issue: 12(5), P. 466 - 466
Published: April 27, 2024
In the current COVID-19 landscape dominated by Omicron subvariants, understanding timing and efficacy of vaccination against emergent lineages is crucial for planning future campaigns, yet detailed studies stratified subvariant, timing, age groups are scarce. This retrospective study analyzed cases from December 2021 to January 2023 in Catalonia, Spain, focusing on vulnerable populations affected variants BA.1, BA.2, BA.5, BQ.1 including two national booster campaigns. Our database includes information such as dates diagnosis, hospitalization death, last vaccination, cause among others. We evaluated impact disease severity age, variant, status, finding that recent significantly mitigated across all although waned six months post-vaccination, except BQ.1, which showed more stable levels. Unvaccinated individuals had higher mortality rates. results highlight importance periodic reduce severe outcomes, influenced variant timing. Although seasonality uncertain, our analysis suggests potential benefit annual >60 years old, probably early fall, if eventually exhibits a major peak similar other respiratory viruses.
Language: Английский
Citations
3
Vaccine, Journal Year: 2024, Volume and Issue: 42(23), P. 126026 - 126026
Published: June 3, 2024
Evaluating how a COVID-19 seasonal vaccination program performed might help to plan future campaigns. This study aims estimate the relative effectiveness (rVE) against severe of booster dose over calendar time and by since administration. We conducted retrospective cohort analysis among 13,083,855 persons aged ≥60 years who were eligible receive at start 2022–2023 campaign in Italy. estimated rVE (hospitalization or death) bivalent (original/Omicron BA.4-5) mRNA vaccines two-month interval different times post-administration. used multivariable Cox regression models, including as time-dependent exposure, adjusted hazard ratios (HR) rVEs [(1-HR)X100]. The decreased from 64.9% (95% CI: 59.8–69.4) October-November 2022 22.0% 15.4–28.0) April-May 2023, when majority vaccinated (67%) had received least 4–6 months earlier. During epidemic phase with prevalent circulation Omicron BA.5 subvariant, ≤90 days earlier was 83.0% 79.1–86.1), compared 37.4% 25.5–47.5) during XBB subvariant. phase, 15.8% 9.1–20.1) 181–369 post-administration dose. In all analyses we observed similar trends between 60–79 those ≥80 years, although estimates somewhat lower for oldest group. A provided additional protection up after which incidence much reduced. results also suggest that subvariant have partly escaped immunity targeting original BA.4-5 strains SARS-CoV-2.
Language: Английский
Citations
3
European Journal of Clinical Investigation, Journal Year: 2024, Volume and Issue: 54(10)
Published: July 30, 2024
Abstract Annual vaccination is widely recommended for influenza and SARS‐CoV‐2. In this essay, we analyse question the prevailing policymaking approach to these respiratory virus vaccines, especially in United States. Every year, licensed vaccines are reformulated include specific strains expected dominate season ahead. Updated rapidly manufactured approved without further regulatory requirement of clinical data. Novel (i.e. new products) typically undergo trials, though generally powered clinically unimportant outcomes (e.g. lab‐confirmed infections, regardless symptomatology or antibody levels). Eventually, current future efficacy COVID‐19 against hospitalization death carries considerable uncertainty. The emergence highly transmissible SARS‐CoV‐2 variants waning vaccine‐induced immunity led plummeting vaccine effectiveness, at least symptomatic infection, booster doses have since been recommended. No randomized trials were performed important updated boosters. both cases, annual effectiveness estimates generated by observational research, but studies particularly susceptible confounding bias. Well‐conducted experimental studies, necessary address persistent uncertainties about vaccines. We propose a research framework which would render results relevant viral seasons. demonstrate that feasible adopting more pragmatic provide strategies on how do so. When it comes implementing policies seriously impact people's lives, require substantial public resources and/or rely widespread acceptance, high evidence standards desirable.
Language: Английский
Citations
3